OncoZenge (ONCOZ) Q2 2025 earnings summary

Executive summary

• BupiZenge™, a non-opioid lozenge for oral mucositis, is advancing to a European Phase 3 trial, with market approval targeted for 2027.

• Funding for the Phase 3 trial is secured via a SEK 30.2 million investment from Yangtian Pharma, a SEK 7.5 million convertible loan from Linc AB, and milestone payments from Molteni.

• Commercial partnerships are in place for Europe (Molteni), the GCC region (Avernus Pharma), and financial backing from Yangtian Pharma, with further global expansion planned.

• The company is also exploring additional indications and geographies, including the U.S. and China, leveraging strong clinical evidence and patent protection.

Financial highlights

• No recurring revenues yet; Q1 2025 net sales of SEK 2.7 million from a milestone payment.

• Operating expenses are around SEK 2.5 million per quarter, expected to rise as the Phase 3 trial begins.

• Sufficient funding is secured for the Phase 3 trial, with additional capital from warrants and milestone payments.

Outlook and guidance

• Phase 3 trial to start in H1 2026, aiming for European marketing authorization in 2027.

• U.S. market entry is planned post-European approval, with a focus on securing a partner for a local Phase 3 study.

• Expansion into China and other regions is contingent on further partnerships and regulatory approvals.